[A20-125] Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69

Last updated 04.02.2021

Project no.:
A20-125

Commission:
Commission awarded on 22.12.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Airways and respiratory system

Indication:

Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year.

Result of dossier assessment:

Added benefit still not proven

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2021-02-04: A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form